huntington's diseases

B2 (Linazolamide intermediate B impurity 2) promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease

Rosolutamide (ALZ-003) is a curcumin analog, an orally active Nrf1 and Nrf2 activator.Rosolutamide modulates oxidative homeostasis, improves mitochondrial function and promotes autophagy, reduces mutant protein aggregation, and decreases intracellular/mitochondrial reactive oxygen species (ROS) levels.Rosolutamide has been used in the study of neurodegeneration such as spinal cerebellar ataxia and Huntington disease. neurodegenerative diseases such as Huntington's disease. Regulates oxidative homeostasis.

Tidembersat is a small molecule compound used to treat and/or prevent degenerative diseases such as Huntington's chorea, schizophrenia, neurological.

Cystamine (2,2'-Disulfanediyldiethanamine) is an inhibitor of transglutaminase and inhibits caspase-3 with an IC50 value of 23.6 μM. Cystamine can be used in studies about Huntington's diseases.

RNA splicing modulator-4 (Compound A) is an orally active, brain-penetrant, and selective modulator of RNA splicing. It regulates alternative splicing events to control the inclusion or exclusion of specific exons in precursor mRNA (pre-mRNA), thereby altering the coding sequence and function of mature mRNA. RNA splicing modulator-4 is promising for research in neurodegenerative diseases (such as Huntington's disease) and cancer.

Auten-99 HBr (Auten-99) is a myotubularin phosphatase Jumpy inhibitor exerting potent neuroprotective effects. AUTEN-99 activates autophagy in cell cultures and animal models. AUTEN-99 appears to effectively penetrate through the blood-brain barrier, and impedes the progression of neurodegenerative symptoms in Drosophila models of Parkinson's and Huntington's diseases. Furthermore, the molecule increases the survival of isolated neurons under normal and oxidative stress-induced conditions. Thus, AUTEN-99 serves as a potent neuroprotective drug candidate for preventing and treating diverse neurodegenerative pathologies, and may promote healthy aging.

AC-VEID-CHO (TFA) is a peptide-derived inhibitor targeting Caspases-6, -3, and -7, with IC50 values of 16.2 nM, 13.6 nM, and 162.1 nM, respectively. This compound demonstrates significant inhibitory potency and is applicable in the study of neurodegenerative diseases, such as Alzheimer's and Huntington's disease [1].

AC-VEID-CHO is a peptide-derived cysteine aspartate-specific protease inhibitor that targets Caspase-6, Casapase-3, and Caspase-7 with IC50 values of 16.2 nM, 13.6 nM, and 162.1 nM, respectively. This compound also inhibits VEIDase activity, showing an IC50 value of 0.49 µM. AC-VEID-CHO is utilized in research concerning neurodegenerative diseases such as Alzheimer's disease and Huntington's disease.

Cystamine-D8 dihydrochloride is the deuterated form of Cystamine (dihydrochloride), which represents the disulfide form of the free thiol cysteamine. Cystamine functions as an orally active transglutaminase (Tgase) inhibitor and also inhibits caspase-3 with an IC50 value of 23.6 μM. It is utilized in research on various diseases, including Huntington's disease (HD).

Cystamine-D8 Dihydrochloride (Standard) is a reference standard of Cystamine-D8 Dihydrochloride intended for quantitative analysis, quality control, and related biochemical research applications. Cystamine-d8 (dihydrochloride) is the deuterated form of Cystamine (dihydrochloride), which represents the disulfide form of the free thiol cysteamine. Cystamine functions as an orally active transglutaminase (Tgase) inhibitor and also inhibits caspase-3 with an IC50 value of 23.6 μM. It is utilized in research on various diseases, including Huntington's disease (HD).

Tat-ASIC1a (1-20) (mouse, rat) is a competitive ASIC1a transmembrane peptide with significant neuroprotective effects. It alleviates acidotoxic neuronal damage by targeting the ASIC1a-RIPK1 pathway and an auto-inhibition mechanism. This compound effectively safeguards the brain in ischemic stroke mouse models against damage from ischemia and is applicable in research on neurodegenerative diseases, such as Huntington's disease and Parkinson’s disease.